Fusion Genes Predict Prostate Cancer Recurrence
Technical Report,15 Sep 2017,14 Sep 2018
University of Wisconsin System Madison United States
Pagination or Media Count:
This Impact Award between the University of Pittsburgh, Stanford University and University of Wisconsin at Madison seeks to provide definitive clinical validation of low copy number transcript fusions as prognostic markers in clinically localized prostate cancer. The University of Wisconsin site is charged with providing formal in fixed paraffin embedded samples for independent validation of markers discovered at University of Pittsburgh. To that end, we have shipped 437 samples for assay testing and have accumulated over 750 FFPE blocks of radical prostatectomy specimens with detailed clinical follow-up. We are performing an update of the clinical follow-up on these patients to maximize length of clinical follow-up. The 3 centers have been communicating electronically and via phone conference. An in person meeting is planned in the spring to review data for the final report. The University of Pittsburgh has been addressing issues with assay artifacts. We will increase the number of samples accumulated to get to our goals. We will be sending specimens blinded to the recurrence data to the Pittsburgh site for the remaining sets. We have agreed to allow the Stanford and Wisconsin sites to receive data from Pittsburgh to perform correlation with clinical data and correlation with outcomes at the outside sites.
- Medicine and Medical Research